RxDoctor Payments DataLook up a doctor →

Charles Burns, NP

Nurse Practitioner · Orchard Park, NYNPI 1437134947

Payments from drug & device makers

$12,151in general payments, 2019–2025

Across 515 payments — averaging $23.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$1K
  • GSK$977
  • Lilly USA, LLC$949
  • Novo Nordisk$530
  • Boston Scientific$507
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$12,151100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,151 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$18,146
Medicare patients
80
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ThiolaTiopronin12$263,225
RybelsusSemaglutide77$131,690
JardianceEmpagliflozin95$125,819
FarxigaDapagliflozin Propanediol100$121,353
Trelegy ElliptaFluticasone/Umeclidin/Vilanter149$114,803
EliquisApixaban58$85,665
Breztri AerosphereBudesonide/Glycopyr/Formoterol83$74,922
MounjaroTirzepatide60$70,777
OzempicSemaglutide47$63,489
XareltoRivaroxaban53$61,959
TrulicityDulaglutide32$43,722
Synjardy XrEmpagliflozin/Metformin Hcl38$42,638
Fluticasone-SalmeterolFluticasone Propion/Salmeterol133$24,800
Xigduo XrDapaglifloz Propaned/Metformin14$20,449
VascepaIcosapent Ethyl28$20,296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$3,225$207,290211 claims
Novo NordiskRybelsus, Ozempic$530$195,179124 claims
Boehringer IngelheimJardiance, Synjardy Xr$344$168,457133 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$977$134,877197 claims
Lilly USA, LLCMounjaro, Trulicity$949$114,50092 claims
PfizerEliquis$356$85,66558 claims
Johnson & JohnsonXarelto$53$61,95953 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Orchard Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →